Blog
Plain language articles on research peptides: new studies, regulatory shifts, and practical safety. Educational only, and never medical advice.
Retatrutide in 2026: new phase 3 data and a closing access window
The strongest weight loss numbers yet landed this year, at the same time a court fight over what retatrutide legally is threatens to end research and compounded access. Here is what the evidence shows and what is actually changing.
4 min readSafePeptideUse
Read article →Where peptide compounding rules stand after the 2026 FDA votes
The FDA spent 2026 deciding which bulk peptides pharmacies may compound. Here is what changed, what the July advisory votes did, and why the rules still leave most research peptides unapproved.
1 min readSafePeptideUse
A vial is only as trustworthy as its Certificate of Analysis
Research material is unregulated, so the label is a claim, not a guarantee. A recent third party Certificate of Analysis is the closest thing to proof you can get before you trust a vial.
1 min readSafePeptideUse